Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Leaf Vertical Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03607643
- Locations
- 🇺🇸
Southwest Cancer Center, Orlando, Florida, United States
QUILT-3.080: NANT Pancreatic Cancer Vaccine
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionBiological: bevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: OxaliplatinBiological: AvelumabProcedure: SBRT
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03586869
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Mona Frolova
- Target Recruit Count
- 48
- Registration Number
- NCT03579004
- Locations
- 🇷🇺
Russian Cancer Research Center named after N.N.Blokhin RAMS, Moscow, Russian Federation
🇷🇺Alexey Tryakin, Moscow, Russian Federation
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Interventions
- Drug: Nab-paclitaxelDrug: GemcitabineDrug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Oxaliplatin
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
- Conditions
- Interventions
- Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: SorafenibProcedure: SBRTBiological: Aldoxorubicin hydrochlorideBiological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Drug: CetuximabBiological: N-803
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563170
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
- Conditions
- Interventions
- Drug: LeucovorinDrug: 5-FluorouracilDrug: Doxorubicin HCLDrug: paclitaxelDrug: Aldoxorubicin HClDrug: nab-PaclitaxelBiological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Drug: AvelumabBiological: ALT-803Biological: haNKDrug: Cyclophosphamide
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03554109
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 537
- Registration Number
- NCT03533582
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 264
- Registration Number
- NCT03532711
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- 1Globe Health Institute LLC
- Target Recruit Count
- 668
- Registration Number
- NCT03522649
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.